Blueprint Medicines (BPMC) Reports In-Line Q2 EPS

Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($1.86), in-line with the analyst estimate of ($1.86). Revenue for the quarter came in at $27.3 million versus the consensus estimate of $19.01 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• First Bancorp. (FBNC) Misses Q1 EPS by 2c
• Newmarket (NEU) Reports Q1 EPS of $11.23